Wednesday, February 13, 2019
Home »
» Medical News Today: New drug shows promise against several aggressive cancers
Medical News Today: New drug shows promise against several aggressive cancers
Initial trials in humans find that a new drug, tisotumab vedotin, shows significant promise in treating stubborn tumors in several late-stage cancers.
Related Posts:
Mosquito repellents tested: DEET is best; plant-based alternatives to it work fine in lower-risk areas if they are reapplied as needed For a larger version of this graph, click on it. To download and save, right-click. By Immo A. Hansen and Hailey A. Luker For The Conversation Now that summer is in full swing, mosquitoes have come out … Read More
Cameron joins other GOP AGs in challenging Biden rule to block access to medical records of women leaving state for abortions Attorney General Daniel Cameron By Melissa Patrick Kentucky Health News Attorney General Daniel Cameron joined fellow Republican attorneys general in opposing a proposed federal privacy rule to shield the medical rec… Read More
State finds several water systems, most on the Ohio, have levels of 'forever chemicals' above a limit being considered by EPA Kentucky Lantern graph from state data, adapted by Ky. Health News By Liam Niemeyer Kentucky Lantern Per- and polyfluoroalkyl substances, commonly known as PFAS or “forever chemicals,” are in Kentucky’s rivers and lakes. Th… Read More
State, far behind on nursing-home inspections, focuses on responding to complaints, but that often takes too long Lexington Herald-Leader graph by John Cheves; click to enlarge "As of June, 73 percent of Kentucky’s 277 nursing homes were listed as going more than two years without a so-called 'annual' inspection. It’s putting pa… Read More
Study shows link between intimate partner violence and risk of developing diabetes People who experience intimate partner violence or the threat of it are much more likely to end up with diabetes, according to a new study published by a University of Kentucky researcher and others. AaronAmat, iStock /… Read More
0 comments:
Post a Comment